Julie C. DiCarlo, Ph.D.
Affiliations: | 2006 | Stanford University, Palo Alto, CA |
Area:
Electronics and Electrical Engineering, Biomedical Engineering, RadiologyGoogle:
"Julie DiCarlo"Parents
Sign in to add mentor| Dwight G. Nishimura | grad student | 2006 | Stanford | |
| (Magnetic resonance imaging of circulation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Peterfy C, DiCarlo J, Emery P, et al. (2019) Use of Magnetic Resonance Imaging to Support Dose Selection in a Phase II Trial of Baricitinib Combined with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. The Journal of Rheumatology |
| Beals C, Baumgartner R, Peterfy C, et al. (2017) Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoring. Plos One. 12: e0187397 |
| Waterton JC, Ho M, Nordenmark LH, et al. (2017) Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting. European Radiology |
| Peterfy C, Strand V, Tian L, et al. (2016) Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials. Annals of the Rheumatic Diseases |
| Peterfy C, Burmester GR, Bykerk VP, et al. (2016) Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Annals of the Rheumatic Diseases |
| MacIsaac KD, Baumgartner R, Kang J, et al. (2014) Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients. Plos One. 9: e113937 |
| Peterfy C, Emery P, Tak PP, et al. (2014) MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Annals of the Rheumatic Diseases |
| Conaghan PG, Peterfy C, Olech E, et al. (2014) The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Annals of the Rheumatic Diseases. 73: 810-6 |
| MacIsaac KD, Baumgartner R, Kang J, et al. (2014) Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients Plos One. 9 |
| Peterfy CG, Olech E, DiCarlo JC, et al. (2013) Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). Arthritis Research & Therapy. 15: R44 |